Eichenfield, Lawrence F. http://orcid.org/0000-0002-2760-0474
Bieber, Thomas http://orcid.org/0000-0002-8800-3817
Beck, Lisa A. http://orcid.org/0000-0002-8452-667X
Simpson, Eric L. http://orcid.org/0000-0002-8793-7087
Thaçi, Diamant
de Bruin-Weller, Marjolein http://orcid.org/0000-0002-1249-6993
Deleuran, Mette http://orcid.org/0000-0003-0593-9925
Silverberg, Jonathan I. http://orcid.org/0000-0003-3686-7805
Ferrandiz, Carlos
Fölster-Holst, Regina
Chen, Zhen
Graham, Neil M. H.
Pirozzi, Gianluca
Akinlade, Bolanle http://orcid.org/0000-0003-2334-5717
Yancopoulos, George D.
Ardeleanu, Marius http://orcid.org/0000-0002-7712-6862
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
Article History
First Online: 7 May 2019
Compliance with Ethical Standards
:
: All studies were conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the International Council for Harmonisation guidelines for Good Clinical Practice and applicable regulatory requirements [CitationRef removed–CitationRef removed]. All patients provided written informed consent before participating in the studies. The studies’ ClinicalTrials.gov identifiers are as follows: NCT01548404, NCT02210780, NCT01859988, NCT02277743, NCT02277769, NCT02260986, and NCT02755649.
: This research was sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The study sponsors participated in the study design collection, analysis, and interpretation of data; writing of the report; and the decision to submit the article for publication. Medical writing/editorial assistance was provided by Vicki Schwartz, PhD, and Manuela Pigors, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
: L. F. Eichenfield has received honoraria for consulting services from Almirall, Celgene, Dermira, Dermavant, Eli Lilly and Company, Forté Pharma, Galderma, L’Oréal, Incyte, MatriSys, Menlo Therapeutics, Otsuka, Novan, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, and Valeant/Ortho Dermatologics; and study support (to institution) from Celgene, Dermira, Dermavant, Eli Lilly and Company, Galderma, Incyte, Medimetriks, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, and Valeant. T. Bieber is a speaker for Almirall, Anacor, Astellas, Celgene, Chugai, Galderma, Janssen-Cilag, L’Oréal, Novartis, Oxagen, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi. L. A. Beck has received honoraria as a consultant and research grants as principal investigator for clinical trials from AbbVie, Pfizer, Realm Therapeutics, and Regeneron Pharmaceuticals, Inc.; has received honoraria as a consultant from AbbVie, Astra-Zeneca, Allakos, Boehringer-Ingelheim, Celgene, Eli Lilly and Company, GSK, Leo Pharma, Novan, Novartis, Realm Therapeutics, Regeneron, Sanofi, and UCB; and is a stockholder in Medtronic and Pfizer. E. L. Simpson has received honoraria for consulting services from AbbVie, Anacor, Celgene, Dermira Pharmaceutical Co., Eli Lilly and Company, Galderma, Genentech, Inc., GSK, LEO Pharma, Menlo Therapeutics, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, and Valeant Pharmaceutical Co.; and has received study support from Anacor, Eli Lilly and Company, GSK, MedImmune, Novartis, Regeneron Pharmaceuticals, Inc., Roivant Sciences, Tioga Pharmaceuticals, Inc., and Vanda Pharmaceuticals, Inc. D. Thaçi has received research support from AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Celgene, Dignity, Eli Lilly and Company, GSK, Janssen-Cilag, LEO Pharma, MSD, Novartis, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sandoz, and Sanofi; received honoraria and is an independent advisor for AbbVie, Celgene, Janssen, La Roche-Posay, LEO Pharma, Medac, Novartis, Pfizer, Inc., Sun Pharma, and UCB; received honoraria and is a consultant for AbbVie, Celgene, Dignity, Galápagos, Novartis, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi, and UCB; and received honoraria and is an advisory board member for AbbVie, Amgen, Celgene, Eli Lilly and Company, GSK, Janssen, LEO Pharma, Mundipharma, Novartis, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sandoz, Sanofi, and UCB. M. de Bruin-Weller is a principal investigator, advisory board member, and consultant for Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme; and a principal investigator and advisory board member for AbbVie. M. Deleuran has received research support, consulting/advisory board agreements, and/or honoraria for lecturing from AbbVie, Eli Lilly and Company, LEO Pharma, Meda, Pierre Fabre, Regeneron Pharmaceuticals, Inc., and Sanofi. J. I. Silverberg has received honoraria for advisory board participation, as a speaker, and for consultancy from AbbVie, Eli Lilly and Company, Galderma, GSK, Kiniksa, LEO Pharma, Menlo Therapeutics, Pfizer, Realm Therapeutics, Regeneron Pharmaceuticals, Inc., Roivant, and Sanofi; and research grants from GSK, Regeneron Pharmaceuticals, Inc., and Sanofi. C. Ferrandiz is a principal investigator in clinical trials for AbbVie, Sanofi, LEO Pharma; and an advisory board participant for Sanofi. R. Fölster-Holst is an investigator for studies, speaker, and consultant for Astellas, Almirall Hermal, Beiersdorf, Johnson & Johnson, La Roche-Posay, LEO Pharma, Neubourg Skin Care GmbH, Novartis, Pierre Fabre, Procter & Gamble, and Regeneron Pharmaceuticals, Inc. Z. Chen, N.M.H. Graham, B. Akinlade, G.D. Yancopoulos, and M. Ardeleanu are employees of and shareholders in Regeneron Pharmaceuticals, Inc. G. Pirozzi is an employee of and may hold stock and/or stock options in Sanofi.